The pre-cycle blood panel is the denominator for every subsequent reading. A bloodwork without baseline is a number without a reference — you cannot detect drift in a value whose starting point is unknown. The clinical significance of any on-cycle result is the delta from baseline, not the absolute value.
The cost-benefit is straightforward: 80–150 EUR at a private direct-to-consumer lab, one 20-minute visit, and the entire on-cycle and post-cycle interpretive framework rests on the output. Skipping it is the single highest-leverage error in protocol design.
The panel structure outlined here mirrors the Endocrine Society’s clinical practice guidelines for testosterone therapy in adult men (Bhasin et al. 2018, J Clin Endocrinol Metab) and the American Urological Association evaluation framework (AUA 2018 Testosterone Deficiency Guideline) — adapted for the supraphysiological exposures characteristic of AAS protocols rather than replacement-dose TRT.
The Essential Panel — What Every Pre-Cycle Draw Must Include
1. Complete Blood Count (CBC) with differential — HGB, HCT, RBC, WBC, platelets. Baseline for erythrocytosis monitoring; the cardiovascular-relevant parameter most likely to shift on any injectable AAS via the EPO-up/hepcidin-down mechanism documented in Bachman et al. 2014, J Gerontol. Reference intervals: HGB 13.5–17.5 g/dL adult male, HCT 38.8–50%, platelets 150–450 thousand/µL.
2. Comprehensive Metabolic Panel (CMP) — fasting glucose, creatinine, BUN, electrolytes (Na, K, Cl, CO2), total protein, albumin, calcium. Establishes kidney function and electrolyte baseline. Trenbolone shows a documented creatinine elevation that is haem-pigment renal excretion artefact rather than true renal injury (Pope & Kanayama 2005, Ann Clin Psychiatry); cystatin C is the GFR marker independent of muscle mass and creatinine for users with chronic supplementation.
3. Lipid Panel — extended — total cholesterol, HDL, LDL (direct preferred over calculated), triglycerides, non-HDL cholesterol. Add ApoB and Lp(a) if the lab offers them. ApoB is the superior cardiovascular risk marker per Sniderman et al. 2019, JAMA Cardiology consensus; target <90 mg/dL general population, <70 mg/dL with risk factors. Lp(a) is the genetic cardiovascular risk marker measured once in life — values >50 mg/dL recalibrate downstream protocol risk decisions independent of all other lipid markers (Tsimikas 2017, JACC).
4. Liver Function — full panel — ALT, AST, ALP, GGT, total and direct bilirubin, albumin. Non-negotiable if any oral compound is on the plan. GGT is sensitive to cholestatic injury before ALT moves (Nasr & Ahmad 2009, Dig Dis Sci); routinely omitted from standard panels — request by name. Direct bilirubin establishes the cholestasis baseline.
5. Total Testosterone — the baseline against which on-cycle shutdown and post-cycle recovery are measured. A 35-year-old starting at 380 ng/dL has different recovery expectations than one starting at 650. The Endocrine Society recommends morning draw (8–10 AM) per circadian variation; total testosterone follows a roughly 30% diurnal swing in young men.
6. Free Testosterone — measured by direct equilibrium dialysis (gold standard, rarely available outside academic labs) or calculated via the Vermeulen equation (1999, J Clin Endocrinol Metab) from total T + SHBG + albumin. The biologically active fraction; the number that maps to symptoms more reliably than total T. Vermeulen-calculated free T loses accuracy at extreme SHBG values (<15 or >80 nmol/L) where direct measurement is preferred.
7. SHBG (Sex Hormone Binding Globulin) — mandatory alongside total and free T. Reference 10–57 nmol/L. Predicts individual compound response: low-SHBG users see amplified effects from stanozolol and oxandrolone; high-SHBG users need dose adjustments upward for comparable clinical effect. Also necessary for free-T calculation. Hammond 2011, J Endocrinol reviewed SHBG as more than a transport protein — it modulates androgen action at the tissue level.
8. Estradiol — sensitive LC-MS/MS assay specifically. Standard immunoassay overestimates low values and underestimates high values in the male reference range; the cross-reactivity error can drive 50–100% measurement deviation per Rosner et al. 2013, J Clin Endocrinol Metab position statement. LC-MS/MS is the reference method. Request by name: LabCorp “Estradiol, Sensitive” (140244), Quest “Estradiol Ultrasensitive LC/MS” (30289), or EU lab equivalent.
9. LH and FSH — pituitary gonadotropin signals. Baseline distinguishes on-cycle shutdown from pre-existing secondary hypogonadism. Men occasionally discover at pre-TRT workup that their LH is already suppressed (idiopathic hypogonadotropic hypogonadism, prior AAS exposure, undiagnosed pituitary lesion); the recovery story is fundamentally different if known at start rather than discovered during PCT. Reference: LH 1.7–8.6 mIU/mL, FSH 1.5–12.4 mIU/mL.
10. Prolactin — clinically critical baseline for any protocol containing 19-nor compounds (nandrolone, trenbolone) or GH/peptide secretagogues. Elevated baseline prolactin (>20 ng/mL in adult male) argues against 19-nor inclusion and warrants pituitary MRI workup to exclude prolactinoma. Melmed et al. 2011, J Clin Endocrinol Metab — Endocrine Society guidelines on hyperprolactinaemia diagnosis and management.
11. TSH, Free T4, Free T3 — full thyroid panel — subclinical hypothyroidism produces fatigue, weight stubbornness, and mood symptoms that get misattributed to the AAS if not ruled out pre-cycle. Free T3 is the biologically active hormone; the panel is incomplete without it. Reference: TSH 0.4–4.5 mIU/L, free T4 0.8–1.8 ng/dL, free T3 2.3–4.2 pg/mL. Garber et al. 2012, J Clin Endocrinol Metab — ATA/AACE guidelines on hypothyroidism evaluation.
12. hsCRP (high-sensitivity C-reactive protein) — systemic inflammation baseline. Inexpensive; highly informative longitudinally. Ridker et al. 2002, NEJM JUPITER trial established hsCRP as independent cardiovascular risk marker. Rising hsCRP across multiple cycles is a tell for undetected chronic inflammation, accelerating subclinical atherosclerosis, or both.
Worth Adding — Higher-Leverage Extensions
HbA1c and fasting insulin — glucose regulation baseline. Mandatory if HGH, insulin-sensitive compounds, or aggressive caloric surplus is planned. HbA1c reflects 3-month average glycaemia; HOMA-IR (calculated from fasting glucose × fasting insulin / 405) is the practical insulin-resistance metric. Matthews et al. 1985, Diabetologia — original HOMA-IR validation paper.
Vitamin D (25-hydroxycholecalciferol) — most trainees are deficient; hormone optimisation stalls at serum 25-OH <30 ng/mL per Holick et al. 2011, J Clin Endocrinol Metab Endocrine Society guidelines on vitamin D evaluation. Supplement to 40–60 ng/mL before cycle initiation; this is independent of compound choice but improves baseline endocrine function.
Ferritin and iron panel — critical baseline if regular phlebotomy is planned for HCT management. Iron depletion from repeated donation produces fatigue disproportionate to HCT reduction; iron overload from supplementation plus donation cessation is the mirror failure mode. Target ferritin 50–150 ng/mL; transferrin saturation 20–45%.
Homocysteine — cardiovascular-risk marker reflecting B-vitamin status (B6, B12, folate). Cheap; worth running once. Elevated values respond to B-vitamin supplementation; cardiovascular outcome benefit of homocysteine reduction is mixed in trials but the marker remains informative.
PSA (prostate-specific antigen) — mandatory at age 40+, recommended at 35+ for any AAS protocol. Baseline is what makes a future rise meaningful. Endocrine Society TRT guideline recommends PSA evaluation pre-treatment in men over 40. Reference: typically <4 ng/mL adult male; lower thresholds in younger men.
Coronary artery calcium (CAC) score — imaging, not blood, but the most predictive cardiovascular marker for the AAS-using population. Greenland et al. 2018, JACC demonstrated CAC’s prediction performance versus standard risk calculators. Baseline at age 40 for long-term users; earlier with strong family history.
DEXA scan — baseline bone density and body composition. Recommended every 3–5 years for long-term users; tracks the slow bone-density changes that crashed-E2 protocols accelerate.
NMR LipoProfile or extended lipid particle analysis — for users with concerning baseline lipid pattern or family history of premature CAD. Provides direct LDL particle number (LDL-P) alongside ApoB, allowing identification of the discordant pattern (normal LDL-C with elevated LDL-P) that standard panels miss.
The EU Context — Where to Draw
Private direct-to-consumer labs across the EU offer pre-built “hormone optimisation” or “pre-cycle” panels at 80–180 EUR:
- Synevo (PL, RO, DE): wide network, sensitive E2 available on request.
- Alpha Laboratories (UK, IE): hormone-focused panels with LC-MS/MS default for steroid hormones.
- Medicover (PL, RO, HU, DE): chain medical labs with comprehensive panels.
- Randox Health (UK): wellness-orientated, premium pricing, broad biomarker coverage.
- Blue Horizon (UK): mail-order finger-prick panels acceptable for some markers, full venous draw for hormones.
Request the sensitive estradiol assay by name regardless of which panel is selected — it is rarely default. Confirm GGT inclusion in the liver panel; some default panels omit it.
Avoid running this through national health insurance. General practitioners will not order hormone panels without clinical indication, and the documented medical record complicates unrelated care later — insurance underwriting, occupational medicine, future specialist referrals.
Interpretation Framework — What the Baseline Enables
The goal at baseline is not “all values in the middle of reference range.” The goal is to know where you sit, so that deltas at week 8 mean something. A testosterone of 380 ng/dL at baseline is not a clinical problem. A testosterone of 380 ng/dL at week 12 of PCT after a 500 mg/week protocol is. Same value, different story — and the only way to tell the stories apart is to have measured both endpoints.
The baseline panel enables specific decisions on the on-cycle bloodwork:
- HCT delta >5 percentage points from baseline: phlebotomy threshold reached; intervene.
- ALT rise >2× baseline: oral compound load is producing predictable hepatic stress; verify trajectory.
- HDL drop >40% from baseline: approaching the threshold below which short-term cardiovascular events become statistically present.
- Total T drop >30% from baseline at PCT week 12: recovery has stalled; clinical intervention indicated.
- Sensitive E2 drop >30% from on-cycle steady-state: AI is suppressing too aggressively; reduce dose.
None of these deltas can be calculated without the baseline endpoint. Without baseline, the on-cycle reading is interpretable only against population-average reference ranges that may not apply to the specific user.
The Defensible Position
No baseline, no protocol. This is not a hardline rule about research ethics — it is the minimum information requirement to operate pharmacologically. The cost is one lab visit and 80–150 EUR. The cost of operating without it is the difference between informed protocol decisions and statistical guesswork against population averages.
The Endocrine Society and AUA TRT guidelines both require baseline labs before therapy initiation, for the same reason: clinical decisions downstream depend on individual baseline data, not on population reference ranges. The supraphysiological exposures of AAS protocols make the baseline requirement more, not less, important than for replacement-dose TRT.